Join
Live feed
·
PRReleasevia Quantisnow
Medicinova Inc logo

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

ByQuantisnow·Wall Street's wire, on your screen.
MNOV· Medicinova Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNOV (Medicinova Inc) and more on Quantisnow.